PRDM14抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using mouse mAb against HEK293 (1), A549 (2), and HepG2 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of A549 cells using PRDM14 mouse mAb (green) and negative control (red).    

  
  

PRDM14 is a transcription factor belonging to the PR domain-containing (PRDM) protein family, characterized by a conserved PR domain homologous to the SET domain found in histone methyltransferases. It plays critical roles in maintaining pluripotency in embryonic stem cells (ESCs), regulating primordial germ cell (PGC) specification, and influencing epigenetic reprogramming during early development. PRDM14 achieves this by repressing genes involved in differentiation, promoting the expression of pluripotency factors like *NANOG*, and modulating DNA methylation and histone modification patterns. Dysregulation of PRDM14 is implicated in cancer, where it can act as an oncogene (e.g., in certain leukemias and breast cancers) or a tumor suppressor, depending on context and epigenetic silencing.

PRDM14 antibodies are essential tools for investigating its expression, localization, and molecular interactions. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and immunohistochemistry to study PRDM14’s role in stem cell biology, germline development, and carcinogenesis. High-quality PRDM14 antibodies are validated for specificity using knockout cell lines or siRNA-mediated knockdown controls, as cross-reactivity with other PRDM family members (e.g., PRDM1/Blimp1) can occur. Species reactivity typically includes human, mouse, and rat. Researchers must select antibodies validated for their specific applications, as functional insights into PRDM14’s dual roles in pluripotency and cancer heavily depend on reliable detection systems.